share_log

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA

Benzinga ·  May 7 20:18
  • ANKTIVA Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product
  • ImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on track to be completed in 12-18 months with capacity to produce a million vials annually
  • Coupled with a recent announcement of BCG availability in partnership with the Serum Institute of India (SII), ImmunityBio has large-scale inventory and capacity for BCG

ImmunityBio, Inc. ((IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for "fill finish" (filling vials and finishing packaging), sufficient for 170,000 doses of 400mcg ANKTIVA...

Login or create a forever free account to read this news
Sign up/Log in
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment